Recombinant Tissue Plasminogen Activator and Mutant rt-PA: Binding Kinetics and Cytotoxicity on Brain Endothelial Cells—Relevance to Brain Hemorrhage

  • F. M. Yatsu
  • R. Alam
  • S. Alam
  • G. Bui
Conference paper


The effectiveness of recombinant tissue plasminogen activator (rt-PA) in thrombolytic therapy is theoretically dependent on the rate at which therapeutically administered rt-PA reaches the clot site and the proportion of rt-PA that is enzymatically active. Interaction between rt-PA and its specific plasma inhibitor PAI-1, and between rt-PA and the endothelial cell lining of blood vessels, are two factors that may limit efficacy. While rt-PA can restore blood flow to thrombosed cerebral arteries and revive function of ischemically impaired brain tissue, rt-PA may also provoke brain damage by causing brain hemorrhage. We report on our studies of rt-PA and mutant rt-PA (TNK), assessing the binding kinetics and cytotoxicity on brain endothelial cells (BEC) to determine their action and relevance in brain hemorrhage.


Plasminogen Activator Thrombolytic Therapy Tissue Plasminogen Activator Human Endothelial Cell Brain Endothelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Levin EG, Loskutoff DJ (1982) Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 94: 631–636PubMedCrossRefGoogle Scholar
  2. 2.
    Dosne AM, Dupuy E, Bodevin E (1978) Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 12: 377–387PubMedCrossRefGoogle Scholar
  3. 3.
    Booyse FM, Osikowicz G, Feder S, Scheinbucks J (1984) Isolation and characterization of a urokinase-type plasminogen activator (Mr = 54000) from cultured human endothelial cells indistinguishable from urinary urokinase. J Biol Chem 259: 7198–7204PubMedGoogle Scholar
  4. 4.
    Sprengers ED, Kluft C (1987) Plasminogen activator inhibitors. Blood 69: 381–387PubMedGoogle Scholar
  5. 5.
    Levin EG (1986) Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood 67: 1309–1313PubMedGoogle Scholar
  6. 6.
    Loskutoff DJ, Edgington TS (1977) Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 74: 3903–3907PubMedCrossRefGoogle Scholar
  7. 7.
    Chmielewska J, Ramby M, Wiman B (1983) Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31: 427–436PubMedCrossRefGoogle Scholar
  8. 8.
    Juhan-Vague I, Moerman B, Decock F, Aillaud MF, Collen D (1984) Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 33: 523–530PubMedCrossRefGoogle Scholar
  9. 9.
    Stern DP, Nawroth D, Handley D, Kisel W (1985) An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci USA 82: 2523–2527PubMedCrossRefGoogle Scholar
  10. 10.
    Barnathan ES, Kuo A, Van der Keyl H, McCrae KR, Larsen GR, Cines DB (1988) Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites. J Biol Chem 263: 7792–7799Google Scholar
  11. 11.
    Vassalli JD, Baccind D, Belin D (1985) A cellular binding site for the Mr 55000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86–92PubMedCrossRefGoogle Scholar
  12. 12.
    Hajjar KA, Hamel NM, Harpel PC, Machman RL (1987) Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 80: 1712–1719PubMedCrossRefGoogle Scholar
  13. 13.
    Hajjar KA, Hamel NM (1990) Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 265: 2908–2916PubMedGoogle Scholar
  14. 14.
    Verstraete M, Collen D (1986) Thrombolytic therapy in the eighties. Blood 67: 1529–1541PubMedGoogle Scholar
  15. 15.
    Passamani E, Hodges M, Herman M (1987) The thrombolysis in myocardial infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous trans-luminal coronary angioplasty. J Am Coll Cardiol 10: 51B - 64BPubMedCrossRefGoogle Scholar
  16. 16.
    Carlson SE, Aldrich MS, Greenberg HS, Topol EJ (1988) Intracerebral hemorrhage complicating intravenous tissue plasminogen activator treatment. Arch Neurol 45: 1070–1073PubMedCrossRefGoogle Scholar
  17. 17.
    Korninger C, Stassen JM, Collen D (1981) Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostasis 46: 658–661Google Scholar
  18. 18.
    Nilsson T, Wallen P, Mellbring G (1984) In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol 33: 49–53PubMedCrossRefGoogle Scholar
  19. 19.
    Emeis JJ, Van den Hoogen C, Jense D (1985) Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemostasis 54: 661–664Google Scholar
  20. 20.
    Fuchs HE, Berger H Jr, Pizzo SV (1985) Catabolism of human tissue plasminogen activator in mice. Blood 65: 539–542PubMedGoogle Scholar
  21. 21.
    Nilsson S, Einarsson M, Ekvarn S, Haggroth L, Mattsson CH (1985) Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. Thromb Res 39: 511–521PubMedCrossRefGoogle Scholar
  22. 22.
    Verstraete M, Bounameaux H, De Cock F, Van de Werf F, Collen D (1985) Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 235: 506–512PubMedGoogle Scholar
  23. 23.
    Declerck DJ, Alessi M, Verstreken M, Kriuthof EKO, Juhan-Vague I, Collen D (1987) Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71: 220–225Google Scholar
  24. 24.
    Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Jones JA, Collen D (1986) Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. Am J Cardiol 58: 573–579CrossRefGoogle Scholar
  25. 25.
    Garabedian HD, Gold HK, Leinbach RC, Jones JA, Yasuda T, Kanke M, Collen D (1987) Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 9: 599–607PubMedCrossRefGoogle Scholar
  26. 26.
    Verstraete M, Su CA, Transwell P, Feuerer W, Collen D (1986) Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemostasis 56: 1–5Google Scholar

Copyright information

© Springer-Verlag Tokyo 1995

Authors and Affiliations

  • F. M. Yatsu
    • 1
  • R. Alam
    • 1
  • S. Alam
    • 1
  • G. Bui
    • 1
  1. 1.Department of NeurologyUniversity of Texas Medical School at HoustonHoustonUSA

Personalised recommendations